Aging-Related Metabolic Disease Research and Drug Development Services

Aging-Related Metabolic Disease Research and Drug Development Services

Aging is a progressive and irreversible pathophysiological process that manifests in the decline of tissue and cellular functions and a significant increase in the risk of various aging-related diseases, including metabolic diseases. While advances in modern medicine have significantly improved human health and extended human lifespan, metabolic diseases such as obesity and type 2 diabetes in older adults pose a major challenge to global public health as societies age. Consequently, an appreciation of the intricate interplay between risk factors and metabolic diseases is of paramount importance for the promotion of well-being and healthy aging.

The interactions between aging and metabolic diseases.Fig. 1 The interactions between aging and metabolic diseases. (Szabo L, et al. 2020)

CD BioSciences provides trusted preclinical contract research services specializing in aging-related metabolic disease research and drug development. With years of experience in the industry, we offer a comprehensive range of services to support our client's research and development needs.

Disease Types Pathogenesis Analysis Biomarker Identification Disease Model Customization Drug Discovery and Development

Pathogenic Mechanism Analysis Services for Aging-Related Metabolic Diseases

CD BioSciences offers a range of analysis services to decipher the pathogenic mechanisms underlying aging-related metabolic diseases, which is crucial for the development of effective therapeutic interventions.

  • Analysis of chronic inflammation. Chronic inflammation, often referred to as "inflammaging," plays a critical role in the development and progression of metabolic diseases. At CD BioSciences, we employ a series of techniques to analyze the inflammatory status in various tissues and cell types. By assessing the levels of pro-inflammatory cytokines, immune cell populations, and signaling pathways, we can elucidate the contribution of chronic inflammation to metabolic disease pathogenesis.
  • Analysis of mitochondrial dysfunction. Mitochondrial dysfunction, one of the key hallmarks of the aging process, has been implicated in the development of metabolic diseases, as it can affect insulin sensitivity, and energy metabolism, and contribute to the progression of obesity and diabetes. We offer analysis services to evaluate mitochondrial function and integrity. Through the assessment of mitochondrial bioenergetics, oxidative stress markers, and mitochondrial DNA damage, we can identify and quantify the extent of mitochondrial dysfunction in aging-related metabolic disease models.
  • Analysis of lipid metabolism dysregulation. Aging-related changes in lipid metabolism can contribute to metabolic diseases. We provide comprehensive lipid profiling and analysis services to assess the alterations in lipid composition, storage, and metabolism in various tissues. By employing advanced lipidomics techniques, we can identify specific lipid species associated with disease progression and evaluate the efficacy of interventions aimed at restoring lipid homeostasis.
  • Analysis of telomere shortening. Accelerated telomere shortening has been associated with metabolic diseases, such as diabetes. We employ specialized techniques to analyze telomere length dynamics and telomerase activity. Through these analyses, we can determine the impact of telomere shortening on cellular function, tissue integrity, and disease progression.
  • Analysis of epigenetic changes. Epigenetic changes can contribute to the dysregulation of metabolic pathways and increase the risk of metabolic diseases. We offer advanced epigenetic analysis services, including DNA methylation profiling and histone modification analysis. By identifying disease-specific epigenetic alterations, we can unravel the molecular mechanisms underlying metabolic diseases and identify novel therapeutic targets.

Biomarker Identification Services for Aging-Related Metabolic Diseases

Our team of experts develops customized biomarker discovery strategies to meet the specific needs of each client and project. We employ a multidisciplinary approach to aging biomarker identification, utilizing advanced technologies and techniques such as genomics, proteomics, metabolomics, and bioinformatics. We apply sophisticated statistical and bioinformatics tools to identify differentially expressed genes, proteins, or metabolites between aging-related metabolic disease and control groups. We employ bivariate correlation analysis to estimate the correlations between variables and age, and also to evaluate the relationship between metabolic biomarkers and aging-related diseases. Integrating and interpreting the data, we can pinpoint potential biomarkers that are significantly associated with aging-related metabolic disease progression, severity, or response to treatment.

Disease Model Customization Services for Aging-Related Metabolic Diseases

We offer aging-related metabolic disease model customization services tailored to meet specific research needs. Utilizing various techniques, such as genetic modification, cell culture optimization, or induction of aging-related disease-like conditions, our team of experts can develop and customize experimental models that closely mimic the pathophysiological features of targeted aging-related metabolic diseases. We ensure that the disease models recapitulate key aspects of the human disease, including relevant metabolic dysregulation, pathological features, and functional abnormalities.

Drug Discovery and Development Services for Aging-Related Metabolic Diseases

CD BioSciences is committed to supporting the drug discovery and development process for aging-related metabolic diseases. We begin by assisting clients in the identification and validation of potential therapeutic targets for aging-related metabolic diseases. We also offer preclinical development support to guide clients perform entire developmental processes. We conduct in vitro and in vivo pharmacology studies to evaluate the efficacy and safety of potential drug candidates. In vitro studies involve testing the candidates in cell-based assays or organoid systems to assess their effects on relevant disease pathways and endpoints. In vivo studies utilize animal models to evaluate the candidates' pharmacokinetics, efficacy, and toxicity profiles.

At CD BioSciences, through our specialized R&D services, we provide comprehensive solutions to support your research goals. Our team of highly skilled scientists and reliable technologies ensure high-quality data and results. If you are interested in our services, please feel free to contact us or make an online inquiry.


  1. Zhang K, et al. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health. Front Public Health, 2023, 11: 1253506.
  2. Spinelli R, et al. Molecular basis of aging in chronic metabolic diseases. J Endocrinol Invest, 2020, 43 (10): 1373-1389.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Are You Ready? Contact Us Now!